Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

COVID-19 to temporarily setback blockchain implementation in global pharmaceutical supply chains

Even though blockchain stands out as a potential solution to improve pharmaceutical supply chains, COVID-19 may become a hindrance rather than a trigger in the technology’s future implementation and uptake, says GlobalData, a leading data and analytics company. Urte Jakimaviciute, MSc, Senior Director of Market Research at GlobalData, comments: “A blockchain-based distributed ledger can provide […]
Read more

Anti-TNF therapies could treat patients with COVID-19-related acute respiratory distress, says GlobalData

Remicade (infliximab) and Humira (adalimumab) are the established anti-tumor necrosis factor (TNF) therapies that have been shown to decrease inflammation in diseases such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). As these anti-TNF therapies reduce inflammation, they could treat COVID-19 patients with acute respiratory distress (ARDS), says GlobalData, a leading data and analytics […]
Read more

India’s Sun Pharma bets on another repurposed drug research for COVID-19 cure, says GlobalData

Following the news that India-based Sun Pharmaceutical Industries Ltd (Sun Pharma) has received Indian regulatory approval to start clinical trials of pancreatitis drug nafamostat mesylate in COVID-19 patients; Prashant Khadayate, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “Sun Pharma being the leading player in India seems to be slightly […]
Read more

Launch of dasatinib generics will be huge financial upside for CML patients in India, says GlobalData

The launch of the generic versions of dasatinib, following the expiration of Indian patent in April 2020 will increase the accessibility for treatment of chronic myeloid leukemia (CML)  and acute lymphoblastic leukemia (ALL) and subsequently result in huge cost savings, says GlobalData, a leading data and analytics company. Post patent expiry of BMS’ Sprycel (dasatinib), […]
Read more

Ferring’s recent Milprosa approval set to partially address unmet need in the female infertility space, says GlobalData

Ferring Pharmaceuticals recently gained FDA approval for Milprosa, a once-weekly progesterone vaginal ring for the luteal phase support in women undergoing Assisted Reproductive Technology (ART) treatment cycles. According to GlobalData, US sales of the various progesterone options used for luteal phase support during ART cycles were estimated at $78M in 2019. By 2028 sales are […]
Read more

Reopening communities involves looking at the epidemiology

As the global COVID-19 crisis continues, countries are taking stock of the current epidemiology information on the disease and attempting to evaluate if it is safe to open their societies again. The number of new cases in several countries has slowed; however, reopening communities too soon may lead to significant spikes in case numbers at […]
Read more

Eligibility questions remain about publicly traded bio/pharma companies that received Paycheck Protection Program loans, says GlobalData

At least 49 publicly traded bio/pharmaceutical companies took Paycheck Protection Program (PPP) loans from the US Government’s $659bn program despite official guidance that the money was not intended for large public companies, says GlobalData, a leading data and analytics company. Peter Shapiro, PhD, PharmSource and Senior Director, Drugs and Business Fundamentals Databases at GlobalData, comments: […]
Read more

Scientific, ethical, legal and practical issues of immunity passports must be addressed before they become a reality

The concept of an immunity passport is under scrutiny and it is crucial that the underlying scientific, ethical, legal and practical issues must be addressed before they become a reality, says GlobalData, a leading data and analytics company. Urte Jakimaviciute, MSc, senior director of market research, commented: “Even though immunity passports could help the world […]
Read more

COVID-19 may have long-term complications and increased long-term costs on the healthcare system

As many COVID-19 patients may experience long-term complications from the illness such as intensive care unit (ICU) delirium, post-traumatic stress disorder (PTSD), lung damage, heart damage and possible neurological issues, GlobalData expects the market for these treatments to increase due to the COVID-19 pandemic as recovered patients may need long-term care for these issues after being released […]
Read more

CCR4 antagonists are a promising combinatorial agent for the future

As novel immuno-oncology (IO) drugs become established in the market, a new trend of combinatorial treatments is arising. The race to develop combinatorial drugs is increasing with more companies including IO potentiating drugs in their pipelines and investigating these in combination with established IO drugs, says GlobalData, a leading data and analytics company. Miguel Ferreira, […]
Read more

Psoriasis digital landscape for patients in Japan offers competent patient engagement, says GlobalData

In Japan, the plaque psoriasis (PsO) treatment landscape is highly competitive with the availability of conventional topical therapies, as well as biologics including anti-TNF, anti-IL-17, anti-IL-23 inhibitors, and a small molecule PDE4 inhibitor. To differentiate within this crowded market, companies offering novel therapies are using branded and unbranded channels to enhance patient engagement throughout all […]
Read more

CVMD clinical trials disrupted by COVID-19 slow to resume and investigation of diabetes drugs intensifies, says GlobalData

The clinical trial landscape has had multiple disruptions due to the COVID-19 pandemic, including the cardiovascular and metabolic disorder (CVMD) space. Despite a few trials resuming, most remain suspended or postponed indefinitely. Within the past two months, there has also been a noticeable uptick in COVID-19-related trials that are focusing on diabetes drugs, according to […]
Read more
1 … 90 91 92 93 94 … 108